alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 1316.8 Employee protected activities.

When so indicated in TVA contract documents or actions, the following clause is included by reference in such documents or actions:

### Employee Protected Activities

(Applicable to contracts for goods or services delivered to nuclear facilities or otherwise relating to Nuclear Regulatory Commission (NRC) licensed activities.)

(a) Contractor shall comply with Section 211 of the Energy Reorganization Act of 1974 (42 U.S.C. 5851), as amended, which prohibits discrimination against employees for engaging in certain protected activities. The Secretary of Labor has determined that “discrimination” means discharge or any other adverse actions that relate to compensation, terms, conditions, and privileges of employment; the term “protected activities” includes, among other things, employees raising nuclear safety or quality controls complaints either internally to their employer or to the NRC. Contractor shall aggressively pursue any employee allegation of discrimination and shall fully investigate such allegations. Contractor shall notify the TVA Concerns Resolution Staff Site Representative of such allegation or complaint in writing, together with a copy of any complaint. Contractor shall provide TVA any investigative reports that it may prepare and shall also provide to TVA a full written description of any management action taken in response to any such allegation or complaint. In circumstances where any such allegation or complaint also charges TVA employees with involvement in any discriminatory activities, contractor shall cooperate fully with TVA counsel in its representation.

(b) Contractor shall ensure that no agreement affecting compensation, terms, conditions, and privileges of employment, including, but not limited to, any agreement to settle a complaint filed by an employee or former employee of the Contractor with the Department of Labor pursuant to Section 211 of the Energy Reorganization Act of 1974, as amended, may contain any provision which would prohibit, restrict, or otherwise discourage an employee or former employee from participating in any protected activity as described in the “Employee Protection” regulations of NRC, 10 CFR 50.7, including, but not limited to, providing information to NRC on potential violations of the NRC's regulations or other matters within NRC's regulatory responsibilities.

(c) Any breach of this provision shall be a material breach of the contract. In the event NRC imposes a civil penalty against TVA as a result of a breach of this provision, such a civil penalty is considered by the parties to be direct and not special or consequential damages.

(d) Contractor agrees to place this provision, along with the flow-down requirement of this sentence, in all subcontracts of any tier entered into pursuant to this contract.

(End of clause)
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
TFC ENTERPRISES, INC. YEAR-END REPORT ON FORM 10-K FOR THE YEAR
ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           2,688
<SECURITIES>                                         0
<RECEIVABLES>                                  154,827
<ALLOWANCES>                                    28,575
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                           6,133
<DEPRECIATION>                                   3,310
<TOTAL-ASSETS>                                 158,583
<CURRENT-LIABILITIES>                          128,721
<BONDS>                                        120,378
<PREFERRED-MANDATORY>                               49
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                      29,813
<TOTAL-LIABILITY-AND-EQUITY>                   158,583
<SALES>                                         40,484
<TOTAL-REVENUES>                                41,920
<CGS>                                                0
<TOTAL-COSTS>                                   26,540
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 8,733
<INTEREST-EXPENSE>                              13,451
<INCOME-PRETAX>                                (6,804)
<INCOME-TAX>                                       792
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (7,596)
<EPS-PRIMARY>                                    (.67)
<EPS-DILUTED>                                    (.67)
        


</TABLE>
**EXHIBIT 32.1****CERTIFICATION**     Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of2002 (18 U.S.C. § 1350, as adopted), J. William Freytag, the Chief Executive Officer of Myogen,Inc. (the “Company”), and Joseph L. Turner, the Chief Financial Officer of the Company, each herebycertifies that, to the best of his knowledge:     **1. **The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2006, towhich this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies withthe requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, asamended; and     **2. **The information contained in the Periodic Report fairly presents, in all materialrespects, the financial condition of the Company at the end of the period covered by the PeriodicReport and results of operations of the Company for the periods covered by the Periodic Report.Dated:May 9, 2006   /s/ J. William Freytag /s/ Joseph L. Turner   J. William Freytag Joseph L. Turner*Chief Executive Officer* *Chief Financial Officer**(Principal Executive Officer)* *(Principal Financial Officer)*     A signed original of this written statement required by Section 906 has been provided toMyogen, Inc. and will be retained by Myogen, Inc. and furnished to the Securities and ExchangeCommission (“SEC”) or its staff upon request. This certification “accompanies” the Form 10-Q towhich it relates, is not deemed filed with the SEC and is not to be incorporated by reference intoany filing of the Company under the Securities Act of 1933, as amended, or the Securities ExchangeAct of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective ofany general incorporation language contained in such filing.
BEFORE HE KICKS DAD OFF 

THE CONSOLE...

Start having short, frequent conversations about alcohol 

and other drugs.

Talking with your child at an early age about drinking and drug use is the first 

step toward keeping them safe. For tips on how—and when—to begin the 

conversation, visit:

www.underagedrinking.samhsa.gov

SMA-18-5085FLY
February 2 8 , 2012



### JUDGMENT 

## The Fourteenth Court of Appeals

ARLINGTON HOME, INC. , Appellant

NO. 14

- 10

- 01000

- CV V.

PEAK ENVIRONMENTAL C ONSULTANTS, INC. D/B /A LIVE OAK ENVIRONMENTLA CONSUL TANTS AND SANDION, L TD, D/B/A COLDWELL

BANKER UNITED REALTO RS , Appellees

____________________ This cause, an appeal from the judgment in favor of appellees, PEAK
ENVIRONMENTAL CONSUL TANTS, INC. D/B/A LI VE OAK ENVIRONMENTAL
CONSULTANTS AND SAND ION, LTD, D/B/A COLD WELL BANKER UNITED
REALTORS , s igned October 4, 2010, was heard on the transcript of the record. We have inspected the record and find the trial court erred in awarding attorney’s fees. We therefore order that the portions of the judgment that award attorney’s fees are
REVERSED and or dered severed and REMANDED for proceedings in accordance with this court’s opinion.

Further, we find no error in the remainder of the judgment and order it
AFFIRMED

.
We order the parties to bear their own costs incurred in this appeal. We further
order this decision certified below for observance.
#### § 115.54 Third-party reporting.

Each facility shall establish a method to receive third-party reports of sexual abuse in its immigration detention facilities and shall make available to the public information on how to report sexual abuse on behalf of a detainee.
FIND NEW WAYS TO TALK 

AS SHE GETS OLDER.

Use everyday moments to have a conversation about 

alcohol and other drugs.

Explain why underage drinking and substance use are dangerous—not just 

because you say so, but because they can significantly impact your child’s 

happiness, health, and safety. For tips on how—and when—to begin the 

conversation, visit 

www.underagedrinking.samhsa.gov

#TalkTheyHearYou PEP20-03-01-045
Hi Chuck,

Earlier this month, myself and members of Neighbors for Clean Air met with John Willoughby and JoyFrank-Collins of Eramet. At that time, they again mentioned an alternative to the full building enclosure

outlined in US EPA’s draft rule and their preference for it. We have decided that we would like to

pursue an independent analysis and comparison of the full building enclosure and their preferred

alternative, with the aim of soliciting public comment and a public hearing in Marietta some time

before the final rule is issued in December.

Both Ohio Citizen Action and Neighbors for Clean Air have always prioritized moving forward with

whatever technology leads to the least toxic air exposure to workers and Eramet’s neighbors. If their

alternative meets the same objective standards as EPA projects for the full building enclosure, wewould gladly promote its adoption, as we also would rather avoid unnecessary allocation of resources

that might otherwise be directed to other pollution prevention efforts. You can understand of course,

why we prefer another independent analysis.

Would it be possible to hold public hearings within this timeframe, perhaps to coincide with any

upcoming site visits you may have planned?

Best,

7Uss 7’. jtisI..

Development Director

2330 Victory Parkway #100

Cincinnati, OH 45206

(513) 221-2100

Like us on Facebook
### SUBCHAPTER LIX–O—NATIONAL PARK OF AMERICAN SAMOA
<PAGE>


                                                                    Exhibit 21.1


                         SUBSIDIARIES OF THE REGISTRANT


<TABLE>
<CAPTION>

NAME OF SUBSIDIARY                                   STATE OF INCORPORATION OR ORGANIZATION
<S>                                                  <C>
West Ad...........................................                  Nevada
Reno Projects, Inc................................                  Nevada
Harveys C. C. Management Company, Inc.............                  Nevada
Harveys L. V. Management Company, Inc.............                  Nevada
Harveys Iowa Management Company, Inc..............                  Nevada
Harveys N.Y. Management Company, Inc..............                  Nevada
Harveys Tahoe Management Company, Inc.............                  Nevada
HCR Services Company, Inc.........................                  Nevada
Harveys Mass. Management Company, Inc.............                  Nevada
Harveys P. C., Inc................................                  Nevada
Harveys BR Management Company, Inc................                  Nevada
HBR Realty Company, Inc...........................                  Nevada

</TABLE>
```

[113th Congress Public Law 265]
[From the U.S. Government Publishing Office]

[[Page 128 STAT. 2942]]

Public Law 113-265
113th Congress

                                 An Act

 
 To reauthorize the Young Women's Breast Health Education and Awareness 
  Requires Learning Young Act of 2009. <<NOTE: Dec. 18, 2014 -  [H.R. 
                                5185]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled, <<NOTE: EARLY Act 
Reauthorization of 2014. 42 USC 201 note.>> 
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``EARLY Act Reauthorization of 2014''.
SEC. 2. REAUTHORIZATION OF THE YOUNG WOMEN'S BREAST HEALTH 
                    EDUCATION AND AWARENESS REQUIRES LEARNING 
                    YOUNG ACT OF 2009.

    Section 399NN(h) of the Public Health Service Act (42 U.S.C. 
280m(h)) is amended by striking ``$9,000,000 for each of the fiscal 
years 2010 through 2014'' and inserting ``$4,900,000 for each of fiscal 
years 2015 through 2019''.
SEC. 3. GAO REPORT ON HHS ACTIVITIES TO PROVIDE BREAST CANCER 
                    EDUCATION.

    Not later than 2 years after the date of enactment of this Act, the 
Comptroller General of the United States shall submit to the appropriate 
committees of the Congress a report--
            (1) listing and detailing the activities of the Department 
        of Health and Human Services that provide or support breast 
        cancer education described in subsection (a), (b), (c), or (d) 
        of section 399NN of the Public Health Service Act (42 U.S.C. 
        280m); and

[[Page 128 STAT. 2943]]

            (2) identifying any such activities that are duplicative 
        with each other or with other Federal breast cancer education 
        efforts.

    Approved December 18, 2014.

LEGISLATIVE HISTORY--H.R. 5185:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 160 (2014):
            Dec. 9, considered and passed House.
            Dec. 15, considered and passed Senate.

                                  <all>
```
# C_2012379EN.01001902.xml

| 8.12.2012 | EN | Official Journal of the European Union | C 379/19 |
| --- | --- | --- | --- |

8.12.2012

EN

Official Journal of the European Union

C 379/19

---

Order of the President of the Court of 14 September 2012 (reference for a preliminary ruling from the Judecătoria Timișoara — Romania) — SC Volksbank România SA v Autoritatea Națională Pentru Protecția Consumatorilor CRPC ARAD TIMIȘ

(Case C-47/11) (1)

1

2012/C 379/32

Language of the case: Romanian

The President of the Court has ordered that the case be removed from the register.

---

(1)  OJ C 113, 9.4.2011.

1

---
UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)November 20,
2008




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
            
            000-23143
            
            13-3379479(State
      or other jurisdiction
              of
      incorporation)
            
            (Commission
              File
      Number)
            
            (IRS
      Employer
              Identification
      No.)777 Old Saw Mill River
      Road, Tarrytown, New York
            
            10591(Address
      of principal executive offices)
            
            (Zip
      Code)Registrant's telephone number,
      including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))




oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))











Item
5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.





(b)           On
November 20, 2008, Paul F. Jacobson resigned as a Director of the
Company and Co-Chairman of the Board of Directors in order to focus his
efforts on a new business venture.  In conveying his resignation, Mr.
Jacobson said, “It has been a pleasure working with Progenics all these years,
and gratifying to be a part of its accomplishments.  I wish the
company and its people all my best for continued success.”





Paul J.
Maddon, M.D., Ph.D., Chief Executive Officer, Chief Science Officer and Founder
of the Company, said, “Paul Jacobson has made many significant contributions to
Progenics during his 18 years of service on our Board. We wish him well in his
future endeavors.”







SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.






PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A.
McKinney


Chief Financial Officer, Senior
Vice President,


Finance & Operations and
Treasurer








Date: November 21,
2008
###### Editorial Note on Part 113

#### Editorial Note:

Nomenclature changes to part 113 appear at 79 FR 55969, Sept. 18, 2014.

#### § 113.107 Clostridium Haemolyticum Bacterin.

Clostridium Haemolyticum Bacterin shall be produced from a culture of *Clostridium haemolyticum* which has been inactivated and is nontoxic. Each serial of biological product containing *Clostridium haemolyticum* fraction shall meet the applicable requirements in § 113.100 and shall be tested for purity, safety, and potency as prescribed in this section. A serial found unsatisfactory by any prescribed test shall not be released.

(a) *Purity test.* Final container samples of completed product from each serial and each subserial shall be tested for viable bacteria and fungi as provided in § 113.26.

(b) *Safety test.* Bulk or final container samples of completed product from each serial shall be tested for safety as provided in § 113.38.

(c) *Potency test.* Bulk or final container samples of completed product from each serial shall be tested for potency using the two-stage test provided in this paragraph.

(1) Each of at least 8 but not more than 10 guinea pigs, each weighing 300 to 500 grams, shall be injected subcutaneously with a guinea pig dose. A second guinea pig dose shall be injected 21 to 23 days after the first dose. Each guinea pig dose shall be one-fifth of the dose recommended on the label for a calf.

(2) *Clostridium haemolyticum* challenge material, available upon request from Animal and Plant Health Inspection Service, shall be used for challenge 14 to 15 days following the last injection of the product. Each of eight vaccinates and each of five additional nonvaccinated guinea pigs for controls shall be injected intramuscularly with approximately 100 LD50 of challenge material. This dose shall be determined by statistical analysis of results of titrations of the challenge material. The vaccinates and controls shall be observed for 3 days postchallenge and all deaths recorded.

(3) For a valid test, at least 80 percent of the controls shall die within the 3 day post-challenge observation period. If this requirement is met, the results of the potency test shall be evaluated according to the following table:

| Stage | Number of vaccinates | Cumulative number of vaccinates | Cumulative total number of deaths for a satisfactory test | Cumulative total number of deaths for an unsatisfactory test |
| --- | --- | --- | --- | --- |
| 1 | 8 | 8 | 1 or less | 3 or more. |
| 2 | 8 | 16 | 4 or less | 5 or more. |

The second stage shall be required only when exactly two animals die in the first stage. The second stage shall be conducted in a manner identical to the first stage.

[39 FR 16862, May 10, 1974, as amended at 40 FR 20067, May 8, 1975; 45 FR 40100, June 13, 1980. Redesignated at 55 FR 35562, Aug. 31, 1990, as amended at 56 FR 66784, 66785, Dec. 26, 1991]
§ 4.3 Removal for unacceptable performance. GAO may reduce in grade/pay level or remove an employee for unacceptable performance in accordance with the provisions of this section. ( a ) *Employee entitlement.* A GAO employee whose reduction in grade/pay level or removal is proposed under this section is entitled to— ( 1 ) An advance written notice of the proposed action which identifies— ( i ) Specific instances of unacceptable performance by the employee on which the proposed action is based; and
( ii ) The critical elements of the employee's position involved in each instance of unacceptable performance.
( 2 ) Be represented by an attorney or other representative.
( 3 ) A reasonable time to answer orally and in writing.
( 4 ) A written decision which— ( i ) Specifies the instances of unacceptable performance by the employee on which the reduction in grade/pay level or removal is based.
( ii ) Unless proposed by the Comptroller General or by a senior manager (e.g., the Deputy Comptroller General, an Assistant Comptroller General, or a Division or Office Director) has been concurred in by an employee who is in a higher position than the employee who proposed the action.
( b ) *Decisions to retain, reduce in grade/pay level or remove.* The decision to retain, reduce in grade or remove a GAO employee— ( 1 ) Shall be made within 30 days after the date of expiration of the notice period, and
( 2 ) In the case of reduction in grade/pay level or removal, may be based only on those instances of unacceptable performance by the employee— ( i ) Which occurred during the 1-year period ending on the date of the notice of the proposed action.
( ii ) For which the notice and other requirements of this section are complied with.
( c ) *Performance improvement.* If because of performance improvement by the employee during the notice period, the employee is not reduced in grade/pay level or removed, and the employee's performance continues to be acceptable for 1 year from the date of advance written notice, any records shall be retained only as prescribed by other recordkeeping requirements, such as grievances, adverse action appeals, or discrimination complaints. In these circumstances any entry or notation of unacceptable performance shall be removed from the employee's official personnel folder and maintained in separate files to be used only in connection with an employee initiated complaint.
( d ) *Appeals.* A GAO employee who has been reduced in grade/pay level or removed under this section is entitled to appeal the action to the GAO Personnel Appeals Board.
( e ) *Nonapplicability.* This section does not apply to— ( 1 ) The reduction to the grade/pay level previously held of a supervisor or manager who has not completed the trial period.
( 2 ) The reduction in grade/pay level or removal of a GAO employee who is serving a trial period under an initial appointment or who has not completed 1 year of current continuous employment under other than a temporary appointment limited to 1 year or less.
( 3 ) Employees in the GAO Senior Executive Service.